{"product_id":"afib-vrio-analysis","title":"Acutus Medical, Inc. (AFIB): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs Acutus Medical, Inc. (AFIB) truly equipped for long-term success? This VRIO analysis cuts straight to the chase, distilling its core competitive edge into the key findings of \u0026amp;O4\u0026amp;. Dive in now to uncover the rare, inimitable assets that drive its performance and what it means for its future.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAcutus Medical, Inc. (AFIB) - VRIO Analysis: \u003cstrong\u003e1. Medtronic Exclusive Manufacturing \u0026amp; Supply Agreement\u003c\/strong\u003e\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at Acutus Medical, Inc. (AFIB) now operating almost entirely as a contract manufacturer, and this Medtronic agreement is the whole story. The takeaway is clear: this deal provides the necessary revenue lifeline but locks the company into a temporary, dependent advantage.\u003c\/p\u003e\n\n\u003cp\u003eHere is the VRIO breakdown for this critical relationship:\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eVRIO Dimension\u003c\/th\u003e\n    \u003cth\u003eAssessment\u003c\/th\u003e\n    \u003cth\u003eCompetitive Implication\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eHigh. It provides a predictable revenue stream tied to a major player's distribution, insulating Acutus from direct competition in the broader ablation market.\u003c\/td\u003e\n    \u003ctd\u003eCompetitive Parity to Temporary Advantage\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eHigh. A multi-year, exclusive OEM manufacturing deal with a top-tier player like Medtronic for a specific portfolio is rare for a company of this size.\u003c\/td\u003e\n    \u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eMedium-High. The specific device technology and the established, streamlined quality systems required by Medtronic are hard to copy quickly.\u003c\/td\u003e\n    \u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eHigh. The entire post-restructuring organization is explicitly aligned to exploit this, focusing solely on manufacturing and distribution.\u003c\/td\u003e\n    \u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eResult\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n    \u003ctd\u003eThe advantage is capped by the agreement's term, which includes contingent payments potentially running through \u003cstrong\u003e2027\u003c\/strong\u003e.\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue: The Financial Anchor\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis agreement is the engine driving Acutus Medical’s current financial structure. For the fiscal year ended December 31, 2024, revenue from continuing operations - which is almost entirely this Medtronic business - hit \u003cstrong\u003e$20.2 million\u003c\/strong\u003e, a massive \u003cstrong\u003e181%\u003c\/strong\u003e jump from the prior year's $7.2 million. That volume helped flip the gross margin from negative \u003cstrong\u003e44%\u003c\/strong\u003e in 2023 to a positive \u003cstrong\u003e5%\u003c\/strong\u003e in 2024. It’s the only game in town right now. The operating loss for continuing operations also dramatically narrowed to just \u003cstrong\u003e$0.1 million\u003c\/strong\u003e, down from $11.7 million the year before. This revenue stream is definitely keeping the lights on.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity and Imitability: The Contract Moat\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSecuring an exclusive manufacturing role with Medtronic for their left-heart access portfolio is not something many smaller firms pull off. The initial deal included an upfront payment of \u003cstrong\u003e$50 million\u003c\/strong\u003e, plus up to \u003cstrong\u003e$37 million\u003c\/strong\u003e in milestones. What makes it hard to copy isn't just the contract itself, but the deep integration. Acutus Medical is now focused on manufacturing these specific left-heart access Products. The barrier to entry for a competitor isn't just replicating the device IP, which Medtronic now owns, but replicating the proven, high-quality manufacturing processes that satisfy Medtronic’s stringent requirements. That operational alignment is tough to replicate on short notice.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization: Lean and Focused\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe organization is lean, which is a direct result of the strategic shift. After restructuring, operating expenses for continuing operations fell to only \u003cstrong\u003e$1.1 million\u003c\/strong\u003e in 2024, down from $8.6 million the prior year. This structure is perfectly organized to maximize the earnout potential. The company is eligible for additional payouts based on sales, with the structure being \u003cstrong\u003e100%\u003c\/strong\u003e of net end-user sales in the first year, dropping to \u003cstrong\u003e50%\u003c\/strong\u003e in the third and fourth years. This structure clearly directs all capital and personnel toward efficient production to hit those sales targets before the contingent period potentially ends around \u003cstrong\u003e2027\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAcutus Medical, Inc. (AFIB) - VRIO Analysis: \u003cstrong\u003e2. Specialized Manufacturing Expertise for Left-Heart Access Devices\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: Deep, proven competency in manufacturing complex transseptal crossing devices, which are critical for accessing the left side of the heart during ablation.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: While Medtronic has internal capabilities, Acutus retains the specific, refined process knowledge for their acquired design.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: Moderate. Competitors could develop similar devices, but replicating the exact, validated manufacturing process takes time and regulatory hurdles.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: High, as the remaining operational team is focused solely on perfecting this manufacturing.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Temporary. Expertise erodes without continuous application or expansion beyond the current contract scope.\u003c\/p\u003e\n\u003cp\u003eThe operational focus is exclusively on the manufacturing and distribution of left-heart access products for Medtronic, following a workforce reduction of approximately 70%. The restructuring incurred estimated pre-tax charges of $1.4 million to $1.8 million. The remaining workforce is 85 total employees.\u003c\/p\u003e\n\u003cp\u003eThe manufacturing expertise supports the portfolio acquired by Medtronic in June 2022, which included an upfront payment of $50 million. Acutus is eligible for contingent consideration payments up to $37 million based on manufacturing and regulatory milestones. Revenue from these sales is expected to continue until January 2027.\u003c\/p\u003e\n\u003cp\u003eThe following table summarizes key financial metrics reflecting the manufacturing-centric operations:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue (2024)\u003c\/td\u003e\n\u003ctd\u003eComparison\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue from Continuing Operations\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$20.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eGrew \u003cstrong\u003e181%\u003c\/strong\u003e year-over-year from $7.2 million in 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Margin (GAAP)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eImproved from negative \u003cstrong\u003e44%\u003c\/strong\u003e in 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating Loss (Continuing Operations)\u003c\/td\u003e\n\u003ctd\u003e$0.1 million\u003c\/td\u003e\n\u003ctd\u003eCompared to $11.7 million the prior year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, Restricted Cash (Dec 31, 2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$14.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDown from $29.4 million the previous year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe specific product lines under this specialized manufacturing agreement include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAcQCross line of sheath-compatible septal crossing devices\u003c\/li\u003e\n\u003cli\u003eAcQGuide MINI integrated crossing device and sheath\u003c\/li\u003e\n\u003cli\u003eAcQGuide FLEX steerable introducer with integrated transseptal dilator and needle\u003c\/li\u003e\n\u003cli\u003eAcQGuide VUE steerable sheath\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe Carlsbad facility maintains FDA registration and a manufacturing license from the California Department of Public Health (CDPH).\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAcutus Medical, Inc. (AFIB) - VRIO Analysis: \u003cstrong\u003e3. Retained Cash Reserves Post-Restructuring and Asset Sale\u003c\/strong\u003e\n\u003c\/h2\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eProvides a crucial financial runway to cover operating expenses until the Medtronic earnouts are fully realized, avoiding immediate capital raises.\u003c\/p\u003e\n\u003cp\u003eThe cash position as of December 31, 2024, was $14.0 million in cash, cash equivalents, marketable securities and restricted cash.\u003c\/p\u003e\n\u003cp\u003eThe operating expenses for continuing operations on a GAAP basis for the full year 2024 were $1.1 million.\u003c\/p\u003e\n\u003cp\u003eThe company received $50 million from the first closing of the asset sale to Medtronic in June 2022.\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eThe specific amount is private, but having a clean balance sheet post-restructuring is a rare positive state in medtech.\u003c\/p\u003e\n\u003cp\u003eThe cash balance as of September 30, 2024, was $12.6 million.\u003c\/p\u003e\n\u003cp\u003eThe cash balance as of March 31, 2024, was $20.0 million.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eLow. Cash is fungible, but the timing of having it post-major divestiture is unique.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eEffective, as the lean structure minimizes burn rate against this reserve.\u003c\/p\u003e\n\u003cp\u003eOperating expenses for continuing operations decreased to $1.1 million in 2024 from $8.6 million in 2023.\u003c\/p\u003e\n\u003cp\u003eThe workforce was reduced by approximately 70% as part of the downsizing expected to be completed in the first quarter of 2025.\u003c\/p\u003e\n\u003cp\u003eThe company is focused on manufacturing and distributing left-heart access products for Medtronic.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eTemporary. This is a depleting asset, not a sustainable advantage.\u003c\/p\u003e\n\u003cp\u003eContingent payments from Medtronic are potentially available through 2027.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancial Metric\u003c\/th\u003e\n\u003cth\u003eDate\u003c\/th\u003e\n\u003cth\u003eAmount (in thousands or specified)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, Marketable Securities, and Restricted Cash\u003c\/td\u003e\n\u003ctd\u003eDecember 31, 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$14,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, Marketable Securities, and Restricted Cash\u003c\/td\u003e\n\u003ctd\u003eJune 30, 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$13,300\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating Expenses (Continuing Operations, GAAP)\u003c\/td\u003e\n\u003ctd\u003eFull Year 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1,100\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating Expenses (Continuing Operations, GAAP)\u003c\/td\u003e\n\u003ctd\u003eFull Year 2023\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$8,600\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInitial Asset Sale Proceeds (Medtronic)\u003c\/td\u003e\n\u003ctd\u003eJune 2022\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$50,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eKey operational expense reduction figures:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eOperating expenses for continuing operations in Q2 2024: $2.2 million.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eOperating expenses for continuing operations in Q2 2023: $4.2 million.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eReduction in workforce: approximately 70%.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAcutus Medical, Inc. (AFIB) - VRIO Analysis: \u003cstrong\u003e4. Existing Regulatory Clearances for Retained Products\u003c\/strong\u003e\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue: Allows the continued, uninterrupted sale and distribution of the left-heart access portfolio through Medtronic, meeting the contract terms.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe value is partially quantified by the initial transaction structure, which included an upfront cash payment of \u003cstrong\u003e$50 million\u003c\/strong\u003e upon the first closing of the left-heart access portfolio sale to Medtronic on June 30, 2022.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity: Standard for a commercialized device, but maintaining clearances while pivoting the business focus is a specific organizational win.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe retained portfolio, prior to the full transition, offered sheath-compatible transseptal access devices that covered an estimated 409,000 electrophysiology and structural heart procedures in the US. US Left-atrial appendage closure (LAAC) procedures were expected to total over 50,000 in 2022.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability: Low. Regulatory clearances are public records, but the maintenance of them under a new structure is the key.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSpecific product clearances for the portfolio include the AcQCross Qx Integrated Transseptal Dilator\/Needle receiving U.S. Food and Drug Administration clearance in 2021 and CE Mark in 2020. An expanded suite of products received a new FDA clearance in June 2022.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization: Effective, as regulatory affairs is likely a small, dedicated function supporting the contract.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe organizational effectiveness is supported by the structure allowing for contingent consideration payments of up to $37 million associated with certain manufacturing and regulatory milestones.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Temporary. Clearances must be maintained and renewed over time.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe advantage is temporary, contingent on achieving milestones that could lead to additional revenue-based earnouts for up to four years following the initial closing.\u003c\/p\u003e\n\n\u003cp\u003eThe retained portfolio products and their associated market context are summarized below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct Line\u003c\/th\u003e\n\u003cth\u003eKey Component\u003c\/th\u003e\n\u003cth\u003eRegulatory Status Example\u003c\/th\u003e\n\u003cth\u003eUS Procedure Coverage Estimate\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcQCross Line\u003c\/td\u003e\n\u003ctd\u003eSheath-compatible septal crossing devices\u003c\/td\u003e\n\u003ctd\u003eAcQCross Qx system received FDA clearance in 2021\u003c\/td\u003e\n\u003ctd\u003e409,000 EP and Structural Heart Procedures\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcQGuide MINI\u003c\/td\u003e\n\u003ctd\u003eIntegrated crossing device and sheath\u003c\/td\u003e\n\u003ctd\u003ePart of the portfolio sold to Medtronic\u003c\/td\u003e\n\u003ctd\u003ePart of the portfolio covering the 409,000 procedures\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcQGuide FLEX\u003c\/td\u003e\n\u003ctd\u003eSteerable introducer with integrated transseptal dilator and needle\u003c\/td\u003e\n\u003ctd\u003ePart of the portfolio sold to Medtronic\u003c\/td\u003e\n\u003ctd\u003ePart of the portfolio covering the 409,000 procedures\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcQGuide VUE\u003c\/td\u003e\n\u003ctd\u003eSteerable sheath\u003c\/td\u003e\n\u003ctd\u003ePart of the portfolio sold to Medtronic\u003c\/td\u003e\n\u003ctd\u003ePart of the portfolio covering the 409,000 procedures\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe regulatory clearances support the manufacturing operations which, in Q3 2024, contributed to a 7% GAAP Gross Margin from Continuing Operations, up from -53% in Q3 2023. For the full year 2024, the Gross Margin was 5%, compared to -44% in 2023.\u003c\/p\u003e\n\n\u003cp\u003eKey aspects of the retained product line's regulatory and commercial status include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe AcQCross Qx system is designed for use with market-leading LAAC devices, including the Watchman implant.\u003c\/li\u003e\n\u003cli\u003eThe system combines the transseptal needle and vessel dilator to reduce equipment swaps during surgery.\u003c\/li\u003e\n\u003cli\u003eThe first closing of the asset sale to Medtronic occurred on June 30, 2022, with an upfront payment of $50 million.\u003c\/li\u003e\n\u003cli\u003eFull Year 2024 Revenue from Continuing Operations, driven by this partnership, reached $20.2 million, an increase of 181% from $7.2 million in 2023.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAcutus Medical, Inc. (AFIB) - VRIO Analysis: \u003cstrong\u003e5. Contractual Relationship with Medtronic\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eInitial upfront cash payment from Medtronic: \u003cstrong\u003e$50 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePotential milestone payments up to \u003cstrong\u003e$37 million\u003c\/strong\u003e plus undisclosed revenue-based payouts.\u003c\/li\u003e\n\u003cli\u003eTriggered a \u003cstrong\u003e$17 million\u003c\/strong\u003e payment upon achieving the second milestone.\u003c\/li\u003e\n\u003cli\u003eEarnout payments based on Medtronic's net sales continue through \u003cstrong\u003eJanuary 2027\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe acquired portfolio includes the AcQCross® line of sheath-compatible septal crossing devices and select AcQGuide® products.\u003c\/li\u003e\n\u003cli\u003eThe deal involved intellectual property rights and manufacturing equipment for the left-heart access devices.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eAmount\/Term\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpfront Payment\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$50 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMaximum Milestone Payouts (Specified)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$37 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEarnout Period End Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eJanuary 2027\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY 2024 Revenue from Continuing Operations\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$20.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2024 Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY 2024 Gross Margin (Continuing Ops)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY 2023 Gross Margin (Continuing Ops)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003enegative 44%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Equivalents (as of December 31, 2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$14.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eDistribution Agreement initial term: Up to \u003cstrong\u003efour years\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eMedtronic became the exclusive distributor by the first half of \u003cstrong\u003e2023\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFollowing restructuring, revenue is \u003cstrong\u003esolely\u003c\/strong\u003e from the sale of Products to Medtronic at specified transfer prices and potential Net Sales Earnouts.\u003c\/li\u003e\n\u003cli\u003eFY 2024 Operating Expenses (Continuing Ops, GAAP) were \u003cstrong\u003e$1.1 million\u003c\/strong\u003e, down from \u003cstrong\u003e$8.6 million\u003c\/strong\u003e the prior year.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe advantage is temporary, expiring following the conclusion of the Net Sales Earnout period in \u003cstrong\u003e2027\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAcutus Medical, Inc. (AFIB) - VRIO Analysis: \u003cstrong\u003e6. Lean, Contract-Manufacturing Focused Organizational Structure\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Dramatically lowers fixed overhead and SG\u0026amp;A (Selling, General, and Administrative expenses), improving the path to profitability based on contract revenue alone. Operating expenses for continuing operations decreased from \u003cstrong\u003e$8.6 million\u003c\/strong\u003e in 2023 to \u003cstrong\u003e$1.1 million\u003c\/strong\u003e in 2024.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Rare for a company that previously aimed to be a market-facing innovator; this is a successful, forced pivot to a pure-play manufacturer. Workforce reduction of approximately \u003cstrong\u003e70%\u003c\/strong\u003e announced in December 2024.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. Competitors could downsize, but few would willingly dismantle their commercial engine so completely. The company exited the electrophysiological mapping and ablation business.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Very high. The organization is now perfectly structured for its singular purpose. The company's exclusive source of revenue will continue to come from the sale of left-heart access products at transfer prices specified in the Distribution Agreement with Medtronic.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. If the company reinvents itself, this lean structure will need to be rebuilt into a growth-oriented one. The company will continue receiving revenue from Medtronic product sales and earnout payments until January \u003cstrong\u003e2027\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThe structure's focus is quantified by the following financial metrics:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eFull Year 2023\u003c\/td\u003e\n\u003ctd\u003eFull Year 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue from Continuing Operations\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$20.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating Expenses (Continuing Operations)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$8.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating Loss (Continuing Operations)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$11.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Margin (Continuing Operations)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-44%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe organizational realignment involved specific workforce actions:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eWorkforce reduction of approximately \u003cstrong\u003e70%\u003c\/strong\u003e announced in December 2024.\u003c\/li\u003e\n\u003cli\u003eA prior reduction of nearly \u003cstrong\u003e65%\u003c\/strong\u003e of employees was announced in November 2023.\u003c\/li\u003e\n\u003cli\u003eRestructuring charges estimated between \u003cstrong\u003e$1.4 million\u003c\/strong\u003e and \u003cstrong\u003e$1.8 million\u003c\/strong\u003e (pre-tax, December 2024).\u003c\/li\u003e\n\u003cli\u003eThe company held \u003cstrong\u003e$14.0 million\u003c\/strong\u003e in cash and equivalents as of December 31, 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAcutus Medical, Inc. (AFIB) - VRIO Analysis: \u003cstrong\u003e7. Residual Intellectual Property (Left-Heart Access)\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e IP that underpins the devices Acutus manufactures for Medtronic, providing a technical moat for the contracted products.\u003c\/p\u003e\n\u003cp\u003eThe value of the Intellectual Property rights to the Left-Heart Access portfolio is evidenced by the transaction with Medtronic, which completed its initial closing on \u003cstrong\u003eJune 30, 2022\u003c\/strong\u003e. The initial cash consideration paid by Medtronic was \u003cstrong\u003e$50 million\u003c\/strong\u003e for, among other things, the intellectual property rights to the portfolio. Acutus remains eligible for contingent consideration payments based on milestones and future sales.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eTransaction Component\u003c\/th\u003e\n\u003cth\u003eFinancial Amount (USD)\u003c\/th\u003e\n\u003cth\u003eTrigger\/Basis\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpfront Cash Payment (Initial Closing)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$50 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTransfer of IP rights and equipment for Left-Heart Access Portfolio.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMilestone Earnout Payment 1\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$20 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOEM qualification achievement.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMilestone Earnout Payment 2\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$17 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSubmission for CE Mark under EU MDR.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Potential Milestone Payments (Stated)\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$37 million\u003c\/strong\u003e more\u003c\/td\u003e\n\u003ctd\u003eBased on achievement of certain milestones.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. It’s the IP not sold off with the AcQMap assets, making it a distinct, retained asset pool.\u003c\/p\u003e\n\u003cp\u003eThe IP retained for the OEM role with Medtronic is distinct from the AcQMap assets, which were subject to a separate acquisition agreement announced July 1, 2025, with EnChannel Medical, which included substantive intellectual property for the mapping platform. The retained IP relates to the portfolio including the AcQCross septal crossing devices, AcQGuide MINI sheath, AcQGuide FLEX Steerable Introducer, and AcQGuide VUE steerable sheath, for which Acutus now acts as a supplier to Medtronic.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. Patents and trade secrets related to the specific crossing mechanism are difficult to reverse-engineer.\u003c\/p\u003e\n\u003cp\u003eThe technical nature of the crossing mechanism IP, which enables access to the left heart for procedures such as left-atrial appendage closure, mitral valve repair, and AF ablation, suggests a high barrier to imitation based on the complexity of the underlying technology.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Effective, as the IP is directly tied to the manufacturing process being executed.\u003c\/p\u003e\n\u003cp\u003eAcutus's business model shifted to solely supporting the manufacturing and distribution of the Products to Medtronic pursuant to the Distribution Agreement, meaning its sole revenue stream comes from the sale of Products to Medtronic at specified transfer prices.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained, provided the patents have long remaining lives.\u003c\/p\u003e\n\u003cp\u003eThe sustained advantage is contingent upon the remaining life of the patents covering the transferred intellectual property rights. Acutus may receive additional payouts based on revenue goals over the next \u003cstrong\u003efour years\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAcutus Medical, Inc. (AFIB) - VRIO Analysis: \u003cstrong\u003e8. Institutional Knowledge of Complex Arrhythmia Treatment\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: The deep, hard-won understanding of electrophysiology (EP) needs from the years spent developing AcQMap, an asset sold for an initial $50 million in June 2022. Prior to this, the company raised $170m in financing in 2019, and $159 million in its 2020 IPO.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: High. This knowledge base is not easily replicated by hiring a few engineers; it requires years of clinical interaction. The EP Devices Market size was estimated at USD 3.8 billion in 2024.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: Very difficult. This is tacit knowledge residing within the remaining, key personnel. The company announced a workforce reduction of approximately 70% in late 2024.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: Moderate. It’s only valuable if the company decides to use it for a new product development effort. Current revenue is heavily dependent on the manufacturing agreement with Medtronic, which includes contingent payments potentially through 2027.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Sustained, if leveraged for the next venture.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eDate\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcQMap Asset Sale Initial Payment\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$50 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eJune 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY 2024 Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$20.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYear ended December 31, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY 2024 Net Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$9.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYear ended December 31, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$14.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDecember 31, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcQMap Sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2019\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWorkforce Reduction\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e70%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAnnounced late 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe depth of experience within the team that developed the initial technology included:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eExecutive experience in the healthcare industry exceeding \u003cstrong\u003e30 years\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eCommercial experience focused on global cardiac device commercialization exceeding \u003cstrong\u003e30 years\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eExperience in clinical trial design and regulatory affairs exceeding \u003cstrong\u003e25 years\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAcutus Medical, Inc. (AFIB) - VRIO Analysis: \u003cstrong\u003e9. Flexibility for Strategic Reinvention\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The financial breathing room and organizational simplicity allow management to evaluate new, smaller-scale technology investments without the pressure of supporting a failing commercial arm.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High. Many companies in this situation are cash-strapped; Acutus has a defined exit path (Medtronic earnouts) to fund a potential next chapter.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low. This is a strategic option, not a tangible resource, but it’s a rare opportunity given the sector's capital intensity.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Potential is high, but the organization is not currently structured for reinvention, only execution.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. This window of opportunity closes once the cash is spent or the Medtronic contract concludes.\u003c\/p\u003e\n\u003cp\u003eThe company's financial position as of year-end 2024 provided a cash and cash equivalents balance of \u003cstrong\u003e$14.0 million\u003c\/strong\u003e. The Q3 2024 cash position was \u003cstrong\u003e$12.6 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThe lean operating expense run-rate for continuing operations in Fiscal Year 2024 was \u003cstrong\u003e$1.1 million\u003c\/strong\u003e, a significant reduction from \u003cstrong\u003e$8.6 million\u003c\/strong\u003e in the prior year. The Q3 2024 operating expenses for continuing operations were \u003cstrong\u003e$0.6 million\u003c\/strong\u003e, resulting in an operating income of \u003cstrong\u003e$0.1 million\u003c\/strong\u003e for the quarter.\u003c\/p\u003e\n\u003cp\u003eThe Medtronic earnout structure provides contingent consideration based on net end-user sales over four years:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eYear 1: \u003cstrong\u003e100%\u003c\/strong\u003e of net sales\u003c\/li\u003e\n\u003cli\u003eYear 2: \u003cstrong\u003e75%\u003c\/strong\u003e of net sales\u003c\/li\u003e\n\u003cli\u003eYears 3 and 4: \u003cstrong\u003e50%\u003c\/strong\u003e of net sales\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe following table compares the annualized lean operating expense run-rate against the potential cash inflow from the Medtronic earnout, using the latest full-year revenue from continuing operations of \u003cstrong\u003e$20.2 million\u003c\/strong\u003e for 2024 as a proxy for the sales volume underpinning the earnout calculation.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eAmount (USD)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCurrent Cash \u0026amp; Equivalents (Dec 31, 2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$14,000,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnualized Lean Operating Expense (FY 2024 Continuing Ops)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1,100,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePotential Annual Earnout (Year 1 Proxy based on $20.2M Revenue)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$20,200,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePotential Annual Earnout (Year 2 Proxy based on $20.2M Revenue)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$15,150,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePotential Annual Earnout (Year 3\/4 Proxy based on $20.2M Revenue)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10,100,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe company received an upfront payment of \u003cstrong\u003e$50 million\u003c\/strong\u003e at the first closing in June 2022, with additional milestone payments including \u003cstrong\u003e$20 million\u003c\/strong\u003e and \u003cstrong\u003e$17 million\u003c\/strong\u003e achieved. Total potential milestone consideration was up to \u003cstrong\u003e$37 million\u003c\/strong\u003e.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516105941141,"sku":"afib-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/afib-vrio-analysis.png?v=1740141593","url":"https:\/\/dcf-model.com\/products\/afib-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}